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Relationship between adipose tissue and fatty liver, and its possible evolution in fibrosis, is supported by clinical and
research experience. Given the multifactorial pathogenesis of non-alcoholic fatty liver disease (NAFLD), treatments for
various contributory risk factors have been proposed; however, there is no single validated therapy or drug association
recommended for all cases which can stand alone. Mechanisms, diagnostics, prevention and treatment of obesity, fatty
liver and insulin resistance are displayed along with recommendations and position points. Evidences and practice can
get sustainable and cost-benefit valuable outcomes by participatory interventions. These recommendations can
be enhanced by comprehensive research projects, addressed to societal issues and innovation, market appeal
and industry development, cultural acceptance and sustainability. The basis of participatory medicine is a greater
widespread awareness of a condition which is both a disease and an easy documented and inclusive clue for
associated diseases and unhealthy lifestyle. This model is suitable for addressing prevention and useful for monitoring
improvement, worsening and adherence with non-invasive imaging tools which allow targeted approaches. The latter
include health psychology and nutritional and physical exercise prescription expertise disseminated by continuous
medical education but, more important, by concrete curricula for training undergraduate and postgraduate students. It
is possible and recommended to do it by early formal teaching of ultrasound imaging procedures and of practical
lifestyle intervention strategies, including approaches aimed to healthier fashion suggestions. Guidelines and
requirements of research project funding calls should be addressed also to NAFLD and allied conditions and
should encompass the goal of training by research and the inclusion of participatory medicine topics. A deeper
awareness of ethics of competences in health professionals and the articulation of knowledge, expertise and skills
of medical doctors, dieticians, health psychologists and sport and physical exercise graduates are the necessary
strategy for detectin a suboptimal health status and achieving realistically beneficial lifestyle changes. “The devil has put
a penalty on all things we enjoy in life. Either we suffer in health or we suffer in soul or we get fat” (Albert Einstein);
the task of medical research and intervention is to make possible to enjoy life also without things that make
sufferance in health and souls and which excessively increase body fat.
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Introduction
Overview on adipose tissue
Ancient bias A good woman had a hen that laid her
every day an egg. Then, the woman had an idea. “I will
feed the hen twice as much food so that she will lay twice
as many eggs!” Instead of one bowl of food for breakfast,
the woman gave the hen two bowls of food for breakfast
every day. Soon, the hen became so fat that it became too
lazy to make any more eggs. So, the woman had no egg
anymore (Aesop, 620–564 BCE). Also, the appreciated
foie gras, the liver of a duck or goose that has been spe-
cially fattened, has a similar history becoming an un-
healthy food from an unhealthy animal, sacrificed in
honour of gastronomy.
Despite the obvious fundamental truth, from the fat to
the liver, to fatty liver and behind, there is a jump, with
likely prejudices of oversimplification. Epidemiological and
interventional evidences outline relationship and likely
mechanisms between peripheral fat excess and vital organ
damage: this is particularly relevant for liver, blood vessels
and heart. Relationship and association are not proof of
causality, and fat content inside adipocytes is quite differ-
ent from fat content in liver and in other cells. The
prompt availability of cheap and high caloric food is a
relatively recent phenomenon, and although it involves
especially the Western countries, it is increasing in a
worldwide fashion.
The smallest molecules with the greatest energy content
are fatty acid, and the cell specialized in their storage are
adipocytes of the white fat. This tissue has the capacity to
accumulate and release rapidly fatty acids and to store
them as triglycerides (TG): in particular situation, such as
obesity, adipocytes hold in their cytoplasm TG and in-
crease their volume by six to seven times [1]. Further-
more, adipose tissue communicates with other organs by
secreting hormones, commonly referred to as adipokines
that mediate the molecular cross-talk that occurs among
adipose tissue, muscle and liver. Among these, leptin in-
creases free fatty acid delivery from adipose tissue to the
liver. Differently, circulating adiponectin is inversely corre-
lated with body fat percentage, promotes insulin sensitivity
and increase glucose utilization and free fatty acid oxida-
tion in the liver [2]. Hypoadiponectinemia together with
other cytokines, i.e. tumour necrosis factor-alpha (TNF-α)
or plasminogen activator inhibitor-1 (PAI-1), induced by
the accumulation of visceral adipose tissue (VAT) might
be a major background of metabolic disorders, including
insulin resistance (IR) and metabolic syndrome (MS)
[3]. Although the ability to contain TG is uncommon
in mammalian cells, adipocytes share it with hepato-
cytes and striated muscle cells. It is well established
that variable amounts of TG are found in the liver of
healthy subjects [1].Hepatic steatosis or fatty liver
Hepatic steatosis or fatty liver is a disease in which lipids
accumulate in the hepatocyte’s cytoplasm with, usually,
an increase in volume of the liver. If alcohol consump-
tion is excluded (less than 20 g/die for women and less
than 40 g/die for men), the term we use is non-alcoholic
fatty liver disease (NAFLD). The prevalence of NAFLD
is around 20%–35% in the general population, and an in-
creasing number of patients presents risk factor for its
development [4,5]; in obese people, instead, prevalence
is about 75% [6]. Asian populations are also experiencing
increased prevalence of Western diseases due to west-
ernized pattern in diet and to a shift toward more un-
healthy lifestyle. It is not a prerogative of adults, since
epidemiological data show that NAFLD affects up to
10% of children, more frequently boys, and prevalence
increases with age. NAFLD is rare in children aged less
than 10 years and usually presents with overweight or
obesity [7]. Paediatric NAFLD should not be underesti-
mated; in fact, a 20-year retrospective longitudinal cohort
study reported that some children progressed to advanced
fibrosis or cirrhosis during follow-up, and others devel-
oped end-stage liver disease with the consequent liver
transplantation. Furthermore, NAFLD is associated with a
significantly shorter long-term survival as compared to
the expected survival of the general population [8].
Western diet and overnutrition is a common cause of this
disease, but not the only one. NAFLD is a multifactorial
disorder that rises from a combination of risk factors, such
as hypertriglyceridemia, obesity and insulin-resistance
(primary NAFLD), but there are also other causes (sec-
ondary NAFLD) such as infectious diseases [9,10]. Hepa-
titis C virus (HCV), mainly genotype 3, interferes with
fat deposition in the liver impairing secretion and deg-
radation and increasing the synthesis of lipids; further-
more, fatty liver is significantly reduced or disappears
after a successful antiviral therapy [11]. Nonetheless,
adenovirus infection, in particular Ad-36, increases fat
storage in adipose tissue but seemingly exerts a protect-
ive effect against NAFLD [12,13]. Ad-36 shows adipo-
genic but also anti-diabetic properties; it up-regulates
peroxisome proliferator-activated receptor gamma (PPARγ)
while increasing glucose uptake. In vitro studies dem-
onstrated that in particular, the E4orf1 protein of Ad-
36 plays a role in the enhanced glucose disposal and
was proposed as a therapeutic agent for NAFLD since
it could exert its effect on hepatocyte metabolism [14].
Furthermore, another virus, i.e. Ad-37, that increases
adiposity in animals and is associated with obesity in
humans too is significantly associated with NAFLD in
non-diabetic patients on an appropriate diet, and it was
hypothesized as adjunctive hallmark of an unfavourable
clinical-metabolic profile, if not a causative factor of
NAFLD [15].
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such as rare disorder of lipid metabolism inherited in a
Mendelian fashion (abetalipoproteinemia, hypobetalipo-
proteinemia or lipodystrophy), glycogen storage disease
or nutritional state such as starvation, total parenteral
nutrition or severe surgical weight loss. The hypothesis
that genetic profile is involved in the pathogenesis of
NAFLD is strengthened by the variability of incidence
in different ethnic populations, suggesting that heritability
and/or environmental factors influence the disease devel-
opment. Polymorphisms in various genes affecting lipid
metabolism, oxidative stress, IR and immune regulation
have been studied as risk factors to the development of
hepatic steatosis, but no one is sufficient to explain the
complex pathogenesis of this disease [16]. It is known that,
despite these evidences, the use of genetics as a tool for
predicting NAFLD is still far from being established.
NAFLD has a heritable component to susceptibility, a
complex trait resulting from environmental exposures
acting on a susceptible polygenic background and com-
prising multiple independent modifiers. Approximately
10 million single nucleotide polymorphisms (SNPs) for
which both possible alleles have a population frequency
of >1% are present in the human genome. Different
genome-wide association studies (GWAS) on NAFLD
were published since 2008, identifying a significant as-
sociation with increased hepatic TG levels for the SNPs
of the PNPLA3 gene [17]. Patatin-like phospholipase
domain-containing 3 (PNPLA3) is an enzyme encodedFigure 1 Relative prevalence of disease from fatty liver to hepatocarcby the PNPLA3 gene related to adipose triglyceride lip-
ase, the major TG hydrolase in adipose tissue. Although
other authors showed that higher NAFLD activity scores
were associated with a variant in farnesyl diphosphate far-
nesyl transferase 1, an enzyme with a role in cholesterol
biosynthesis [18], PNPLA3 represents the only gene that
has been consistently identified across multiple GWAS as
a potential modifier of both hepatic TG accumulation
and clinical biochemistry indices as raised serum alanine
aminotransferase (ALT) levels. In addition, one variant
PNPLA3 gene, S453I, was found to be common in African
Americans compared with European Americans and
Hispanics and it was associated with a lower hepatic fat
content confirming the epidemiological evidence [19].
In some cases, medications may cause liver steatosis,
for example, highly active antiretroviral therapy, amioda-
rone, methotrexate or tamoxifen. Finally, patients with ce-
liac disease often show elevated transaminase levels and
they have an increased risk to develop fatty liver [20]. In
the attempt to find single biomarkers useful as predictive
tools for liver disease and NAFLD, research studies were
addressed to its genetic profile. When steatosis is associ-
ated with detrimental inflammatory cascade (approxi-
mately 10%–25% of patients with NAFLD), due to severe
hepatic lipotoxicity, this condition in named non-alcoholic
steatohepatitis (NASH) and it can progress to cirrhosis
and, in some cases, to hepatocarcinoma (Figure 1); the
interaction of other factors, including lifestyle features, is
equally relevant (Figure 2). Free fatty acids (FFA), ininoma; the most likely associated mechanisms.
Figure 2 Cause and co-factors leading fatty liver to HCC.
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are responsible for liver damage through hepatocyte apop-
tosis (lipoapoptosis), and FFA serum levels correlate with
the severity of the disease [21]. Liver is responsible of the
energy homeostasis, playing a central role in the storage of
glucose as glycogen and in the distribution of glucose and
fatty acid as energy fuels for the other organs. The intrahe-
patic accumulation of lipid droplets can be summarized in
these simple steps: 1) increased uptake of lipids, 2) ele-
vated de novo synthesis of fatty acids, 3) impaired lipopro-
tein synthesis or secretion and/or 4) reduced fatty acid
oxidation [22]. Hepatic glucose and FFA uptake occurs in
an insulin-dependent way; after meals, lipids are trans-
ported as chylomicrons from the gut to the liver through
the lymphatic system. Here, they are stored, processed
and assembled with apolipoprotein B100 (ApoB) to form
very-low-density lipoprotein (VLDL) and then secreted to
be stored as lipids in the adipose tissue [23]. The liver does
not typically function to store excessive amounts of lipids
as energy reserves for the body. When a dietary overload
occurs, as in the high-fat and high-carbohydrates western
diet, it may result in hepatic lipid accumulation, due also
to the de novo fatty acid synthesis from carbohydrate me-
tabolism through acetyl-CoA. In NAFLD patients, there is
an elevated level of circulating FFA, probably due to loss
of sensitivity to insulin in the adipose tissue and to defect
in the suppression of lipolysis [24]. Then, there is a shift
from lipolysis to de novo fatty acid synthesis in livers of
insulin-resistant people.Initially, there is a reversible intracellular deposition
of lipids that leads, through molecular modifications, to
oxidative stress and cytokine-induced liver damage, due
also to Kupffer cell activation responsible for oxidative
stress defense and pro-inflammatory cytokine release.
Elevated reactive oxygen species (ROS) lead to organ-
elle toxicity, suppression of fatty acid oxidation and inhib-
ition of lipoprotein assembly and secretion that contribute
to TG deposition in the liver [25]. Insulin potently sup-
presses lipolysis in adipose tissue. However, in a condition
involving IR, such as NAFLD, this suppression is frus-
trated, resulting in an increased efflux of FFAs from
adipose tissue. The hyperinsulinemia associated with IR
leads to the up-regulation of sterol regulatory element-
binding protein-1c (SREBP-1c), which is a key tran-
scriptional regulator of the genes involved in de novo
lipogenesis and to the inhibition of β-oxidation of FFAs,
resulting in the stimulation of lipid accumulation in the
liver [26] (Figure 3). Small fat vacuoles (liposomes) around
the nucleus (microvesicular fatty change) are the earlier
modification: liver cells are filled with multiple fat droplets
that do not displace the centrally located nucleus. There-
after, an incremental size increase of the vacuoles occurs
and the nucleus is pushed to the periphery with the char-
acteristic signet ring appearance (macrovesicular fatty
change). These well-defined vesicles are optically “empty”
because fats vanish during histology processing. Coales-
cence of large vacuoles into fatty cysts leads to irreversible

















Figure 3 Fatty liver pathogenesis. Representation of the step-by-step progression of the fatty liver pathogenesis, with its respective pathologic
features.
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corticosteroids. There are two discrete forms of steato-
sis that may be found in patients infected with HCV.
Metabolic steatosis can coexist with HCV, regardless of
genotype, in patients with risk factors such as obesity,
hyperlipidemia and insulin resistance. The second form
of hepatic steatosis in HCV patients is a result of the
direct cytopathic effect of genotype 3 viral infections; it
is a macrovesicular steatosis directly related to the bur-
den of the HCV RNA load and distributed in the peri-
portal areas rather than the centrilobular region which
is more commonly seen in NAFLD [27].
A special case is focal fatty liver which is a liver area
of localized or patchy imaging, usually by ultrasound,
of lipid accumulation. Pathogenesis is not always clear
and it is seemingly a condition different from NAFLD
and NASH which are widespread and quite uniform
conditions, despite that it may result from altered ven-
ous flow to liver, tissue hypoxia and malabsorption of
lipoproteins. The condition has been increasingly de-
tected by abdominal imaging studies and is most com-
monly occurring subjacent to the liver capsule. We can
face a focal fat deposition within an otherwise normal
liver or diffuse fat deposition with focal sparing. Focal
fat sparing in particular may be confused with liver me-
tastases, and a fine needle biopsy is sometimes per-
formed to differentiate it from malignancy. Our view is
different. Despite that the appearance of focal areas of
decreased echogenicity in a fatty liver has previously,and currently, been interpreted solely on the basis of their
contrast with the surrounding tissue, so that segmentally
or subsegmentally distributed hyperechoic areas have been
attributed to focal accumulations of fat in an otherwise
normal liver, an accurate biopsy study reported carefully
that hypoechoic focal lesions within a “bright” steatotic
liver are not areas that have been spared by the process of
fatty infiltration and, conversely, that focal areas of in-
creased echogenicity should not be considered to reflect
localized accumulations of fat surrounded by normal par-
enchyma. The difference between these lesions and the
hepatic parenchyma surrounding them appears to lie in
the organization of this fat into lipid droplets. So,
organization of fat into a large number of small drop-
lets would thus be expected to produce a relatively
hyperechoic image, although the same quantity of fat
divided into a few larger droplets should be reflected in
relatively hypoechoic imaging. Focal defects are likely
to be areas with different patterns of fatty infiltration as
compared with the surrounding tissue, their echogeni-
city depending on the adjustment of the time-gain
compensation curve of the scanner; this may also ex-
plain the extreme diversity with which these lesions
have been described. The reasons for these irregular-
ities in the organization of the fatty deposits are still
unclear. Regional differences in blood flow may play an
important role in the intrahepatic distribution of fat,
but it is also possible that these differences are a result,
rather than a cause, of fat deposition, which leads to
Trovato et al. The EPMA Journal 2014, 5:21 Page 6 of 24
http://www.epmajournal.com/content/5/1/21elevations in portal vein pressure [28]. To understand the
NAFLD pathophysiology, numerous animal models (nu-
tritional and genetic) were considered. Data obtained from
animal experiments are quite homogenous in contrast
with the heterogeneity of the human population. The high
inter-individual variability concerns genetic background,
comorbidities, physical activity, drugs, diet, lifestyle, etc.
Thus, the translatability of the data to humans is limited.
The use of dietary models of NAFLD is more relevant
than genetic models because few NAFLD patients exhibit
evident genetic defects or specific profiles. Most studied
are the models with increased lipid import or synthesis in
the liver (high-fat diets, high-fructose/sucrose diets,
combined diets) or reduced lipid export or catabolism
(methionine- and choline-deficient diet; choline-deficient,
L-amino acid-defined diet). Since NAFLD has a polygenic
genetic background, monogenic mouse models do not
fully mirror human NAFLD, but they may provide some
information concerning particular events in the patho-
physiology of NAFLD.
Steatohepatitis and fibrosis
Hepatocytes are not the only type of liver cells contribut-
ing to steatosis; actually, there is an intensive exchange of
molecules among endothelial cells, fibroblasts, cholangio-
cytes, stellate cells, Kupffer cells and other types of cells
such as leukocytes. In steatotic liver, sinusoidal space is
markedly reduced and altered due to the compression by
fat-rich hepatocytes as well as the infiltration of macro-
phages (Kupffer cells) leading to alteration in endothelial
signaling toward leukocyte recruitment and activation.
Fatty acids may contribute to pro-inflammatory stimu-
lation of leukocytes or macrophages, leading to liver
cell injury and disease progression. Cytokines, particularly
TNF-α, IL-1b and interleukin-6 (IL-6), are involved in the
recruitment of circulating macrophages into the liver and
the activation of Kupffer and hepatic stellate cells (HSCs),
both contributing to the progression from simple steatosis
to steatohepatitis. In humans, serum levels of TNF-α are
significantly higher in patients with simple steatosis and
NASH than in normal subjects, and TNF-α levels correl-
ate with the stage of fibrosis and with the NAFLD activity
score (NAS) in NASH [29]. Activated Kupffer cells, infil-
trating monocytes, activated and aggregated platelets, and
damaged hepatocytes are the sources of platelet-derived
growth factor (PDGF) and tumour growth factor beta-1
(TGF-β1), which trigger the initiation of intracellular sig-
naling cascades that stimulate the proliferation and
phenotypic transformation of HSCs into myofibroblast-
like cells (MFB), producing collagen [30]. Simultan-
eously with steatohepatitis, hepatic fibrosis may occur.
It is characterized by the overproduction of extracellu-
lar matrix proteins, such as collagen type I and III, and
preferred deposition in the subendothelial space ofDisse leading to the formation of an incomplete suben-
dothelial basement membrane, creating additional diffu-
sion barriers between hepatocytes and the liver sinusoid
(“capillarization of sinusoids”) [31]. The development of
MFB is the result of a multistep sequence, which origi-
nates from liver cell necrosis induced by various noxious
agents (toxic, immunologic). Stellate cells are also acti-
vated by long-chain polyunsaturated fatty acid [31] and by
hormones; the rennin-angiotensin-aldosterone system, for
example, plays a role in the fibrosis onset [32]. TGF-β1 is
one of the cytokines primarily responsible for these effects
and for decreased degradation of matrix proteins [33]. In
NAFLD, oxidative stress inhibits the replication of mature
hepatocytes, leading to the expansion of the hepatic pro-
genitor cell (oval cell) population. The number of oval
cells is reported to correlate with the stage of fibrosis in
patients with both alcoholic fatty liver disease and
NAFLD. Thus, excessive hepatocyte cell death and in-
adequate oval cell proliferation are thought to be in-
volved in NASH fibrogenesis [34]. Experimental studies
suggest that uncontrolled hepatocyte apoptosis may be
a central mechanism triggering liver fibrogenesis and fi-
brosis [35]. DNA from apoptotic hepatocytes acts as an
important mediator of HSC differentiation by providing
a stop signal to mobile HSCs when they have reached
an area of apoptosing hepatocytes and inducing a sta-
tionary phenotype-associated up-regulation of collagen
production [36] (Figure 3).
Diagnosis
Steatohepatitis is characterized microscopically by stea-
tosis with mixed lobular inflammation, ballooning de-
generation of hepatocytes (sometimes with identifiable
Mallory bodies), glycogenated hepatocyte nuclei and
pericellular fibrosis. There is also a “chicken wire” pat-
tern of pericellular fibrosis, which affects portal areas
only secondarily in later stages.
Clinical assessment NAFLD is an asymptomatic disease;
usually, people do not know that their liver is damaged by
the presence of fat, even when inflammation is present.
Some patients report fatigue or malaise and a sensation of
fullness or discomfort in the right hypochondrium i.e. a
suboptimal health status. In most cases, hepatomegaly is
the only physical sign. Anthropometric indicators of re-
gional adiposity including waist circumference (WC) that
correlates with visceral fat (VF), body mass index (BMI),
expression of total body fat and waist-to-hip ratio (WHR)
are associated to liver injury and fibrosis in NAFLD. WHR
is the most important anthropometric indicator for the
prediction of NAFLD and independent of other risk fac-
tors for metabolic syndrome. Moreover, other anthropo-
metric measures are also closely associated with the
occurrence of NAFLD [37]. This indicates that central
Table 1 The NAFLD activity score (NAS)
Histological features Description Score








Hepatocellular ballooning No 0
Moderate ballooning 1
Evident ballooning 2
It provides a numerical score for patients with NASH. NAS is the sum of the
separate scores for steatosis (0–3), lobular inflammation (0–3) and hepatocellular
ballooning (0–2). The majority of patients with NASH have a NAS score of ≥5.
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some gender differences: in fact, unlike in males, the de-
gree of fat deposition in the liver correlated well with VF
area at the umbilicus in females, but WC had no correl-
ation with lipid liver content. One explanation may be
that probably in females, not only visceral but also sub-
cutaneous adipose tissue (SAT) contributes to WC at
the umbilical level [38]. Moreover, in another study,
men and women with lower arm fat depots and women
with bigger WC have a greater likelihood of liver injury.
So, simple anthropometric measurements of peripheral
fat deposits may help stratify liver disease risk [39]. La-
boratory abnormalities may be also found; serum levels of
aspartate aminotransferase (AST) and ALT could be
mildly to moderately elevated. The ratio AST/ALT is usu-
ally less than 1 and it could be a useful tool to distinguish
NAFLD from steatosis of alcoholic origin, where often the
ratio is 2 or more [40]. Unfortunately, the ratio increases
as fibrosis advances, losing its accuracy in patients with
non-alcoholic cirrhosis [41]. Serum alkaline phosphatase,
γ-glutamyltransferase, or both are over the normal
range in many patients, although the levels usually are
less than those found in patients with alcoholic hepatitis.
When the disease progress to the cirrhotic stage, hypoal-
buminemia, prolonged prothrombin time, hyperbilirubi-
nemia and diminished platelet count are common.
Although pathologic diagnosis through liver biopsy re-
mains the gold standard for the diagnosis, radiological
non-invasive scans are widely used. Biopsy specimens may
be not adequate and representative of the entire liver, with
a high degree of sampling variability, significant intra- and
inter-observer variability in histological staging and has a
small, but real, risk of complications (mainly bleeding), pa-
tient’s discomfort or pain. NAS is a histologic scoring sys-
tem developed and validated by the Pathology Committee
of the NASH Clinical Research Network, which addresses
the full spectrum of lesions of NAFLD. The scoring sys-
tem comprised 14 histological features, 4 of which are
evaluated semi-quantitatively: steatosis (0–3), lobular in-
flammation (0–3), hepatocellular ballooning (0–2) and fi-
brosis (0–4). Another nine features are recorded as
present or absent. A NAS of 5 or greater is consistent with
NASH, while a score of less than 3 can exclude this diag-
nosis [42] (Table 1; Figures 4 and 5).
Radiological tools Ultrasound (US) is a low-cost, prompt
and non-invasive tool to make diagnosis of NAFLD. Fatty
infiltration produces a diffuse increase in echogenicity as
compared with that of the cortical part of the right kidney
(bright liver). Several authors use a score (bright liver
score, BLS) to grade the severity of steatosis [43] (Figure 6).
US assessment is operator dependent, so that the inter-
observer variability is a drawback. On computed tomog-
raphy (CT) scan, the presence of fat leads a low-densityhepatic parenchyma. Steatosis involves all parenchyma in
a large amount of patients, but in some cases, the disease
is not diffuse but focal. In this situation, US and CT could
misinterpret as showing masses of uncertain significance
or actual malignancy. In these cases, contrast-enhanced
ultrasound (CEUS) or magnetic resonance imaging (MRI)
can differentiate easily space-occupying lesions from focal
fatty infiltration or focal fatty sparing (isolated areas of
normal liver in the context of steatosis). CEUS uses micro-
bubble to enhance and improve the US imaging; it can be
used as a kinetic tracer to assess the severity of liver dis-
ease, underlining the local and systemic hemodynamic
changes that accompany chronic liver disease [44]. “Tran-
sit time” curves are generated by tracking the passage of a
peripherally administered intravenous microbubble bolus
through the circulation [45,46]. These times have not yet
been validated in NAFLD but even if some studies of the
parenchymal phase of contrast enhancement have shown
decreased signal intensity in NASH patients, this is only a
conjectural insight for the detection of NASH [47]. MRI
may quantify hepatic steatosis based on the signal differ-
ences between fat and water. Limitation of this scan in-
clude costs, inability to use it in patients with implantable
devices or those with claustrophobia, and altered values
in patients with iron overload [48]. Proton magnetic
resonance spectroscopy (1H-MRS) gives a quantitative
assessment of fatty infiltration of the liver. It is an ef-
fective, non-invasive technique that can be used to
diagnose and quantify hepatic steatosis corresponding
with histopathologic grades [49]. A recent meta-analysis
showed that MRI and 1H-MRS have more accuracy than
US and CT in the diagnosis of NAFLD. These findings
suggest that MRI and 1H-MRS also perform better than
US and CT for detecting separate disease grades, espe-
cially for mild disease (<30% steatosis). This is of great im-
portance in clinical practice when an accurate estimation
Figure 4 Morphological and histological analysis of a liver sample. Haematoxylin and eosin (H&E) staining in liver tissue demonstrated no
sign of tissue degeneration, with a good preservation and absence of lipid droplets. NAFLD activity score = 0 for every histological feature.
Magnification × 20; scale bar: 100 μm.
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benefits of MRI and 1H-MRS over US are the quantitative
measurements which have minor subject to inter- and
intra-observer variability. Disadvantages of CT are the ra-
diation exposure and factors affecting the accuracy of the
results, such as imaging parameters or iron accumulation
[50]. The severity of hepatic steatosis can be accurately de-
termined radiologically only when there is a moderate orFigure 5 Morphological and histological analysis of a liver sample. H&
with a good preservation and the beginning of formation of lipid droplets
inflammation, 1 for hepatocellular ballooning and 0 for fibrosis. Magnificatisevere (>33%) fatty infiltration of the liver documented by
a liver biopsy. Moreover, despite the excellent sensitivity
in detecting significant steatosis, radiological modalities
are unable to distinguish between NAFLD and NASH
[51]. There are, however, imaging techniques that can as-
sess fibrosis non-invasively such as transient elastography
(FibroScan) and acoustic radiation force impulse (ARFI),
which use the US waves to measure the liver stiffness,E staining in liver tissue demonstrated no sign of tissue degeneration,
(black arrows). NAFLD activity score = 1 for steatosis, 0 for lobular
on × 20; scale bar: 100 μm.
Figure 6 Bright liver score. The severity of steatosis can be evaluated by ultrasonography as fatty infiltration in the liver produces a diffuse
increase in echogenicity.
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elastography (MRE) uses the differing viscoelastic prop-
erties of healthy and disease livers, being an MR-based
technique. FibroScan consists of an US transducer that
cannot visualize any image but can assess the elasticity
of the tissue measuring the velocity of the waves; a
limitation is the difficulty in accurately assessing obese
patients, frequently affected by NAFLD. A new XL
probe was used for this kind of patients with less fre-
quent failure of measurement; discordance between
liver fibrosis estimated by biopsy and TE using the
FibroScan XL probe was infrequent, but patients with
severe obesity and elevated liver stiffness have the
greatest risk of discordance [52]. It is reported that the
velocity of elastic waves is faster in fibrotic liver than in
normal liver. The mean cutoff for the diagnosis of sig-
nificant fibrosis and cirrhosis were 0.84 and 0.94, re-
spectively, so that FibroScan is rather accurate for the
diagnosis of high grades of fibrosis [53]. Moreover, the
controlled attenuation parameter (CAP), evaluated with
transient elastography, could efficiently evaluate steato-
sis grades [54]. ARFI is, differently, an US-based elasto-
graphy method that is integrated in a conventional US
machine enabling the exact localization of measure-
ment site. A recent study reported no significant differ-
ence in diagnostic accuracy for the non-invasive
assessment of liver fibrosis between transient elastogra-
phy and ARFI [55].
Serum markers
Several diagnostic panels have been proposed to pre-
dict steatosis and fibrosis based on serum measure-
ments. SteatoTest (ST) and NashTest (NT) would permit
a simple and non-invasive semi-quantitative estimate ofsteatosis and NASH combining 13 parameters: age,
sex, height, weight, triglycerides, cholesterol, alpha-2-
macroglobulin, apolipoprotein A1, haptoglobin, gamma-
glutamyltranspeptidase, transaminases ALT, AST and total
bilirubin [56], but their reliability is not demonstrated.
NAFLD liver fat score was derived from a Finnish popula-
tion as useful tool in identifying patients who may be at
risk of developing non-alcoholic steatohepatitis and as
help to address the selection of the appropriate anti-
hyperglycemic drugs for type 2 diabetic patients. The
score incorporates simple variables such as the presence
of metabolic syndrome and type 2 diabetes mellitus,
fasting serum insulin, AST level and AST/ALT ratio
[57]. FibroTest (FT) is the most frequently used serum
fibrosis marker and consists of an algorithm of five fi-
brosis markers (alpha-2-macroglobulin, apolipoprotein
A1, haptoglobin, GT, bilirubin). The enhanced liver
fibrosis (ELF) test consists of an algorithm of three fi-
brosis markers (hyaluronic acid, amino-terminal pro-
peptide of type III collagen, tissue inhibitor of matrix
metalloproteinase-1). It was claimed that FibroTest and
ELF can be performed with comparable diagnostic ac-
curacy for non-invasive staging of liver fibrosis [58], but
their actual clinical validation is not achieved nor con-
firmed. The AST/platelet ratio index (APRI) is another
good estimator of hepatic fibrosis [59], whose reliability
is not demonstrated. Another group of researchers de-
veloped the NAFLD fibrosis scoring system using six
commonly measured parameters that are independent
indicators of advanced liver fibrosis (age, hyperglycemia,
BMI, platelet count, albumin and AST/ALT ratio). They
reported that this method could easily separate patients
with NAFLD with and without advanced fibrosis, so that
liver biopsy for identification of advanced fibrosis would
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(75% or more). The NAFLD fibrosis score is an example
of an indirect panel marker, which includes clinical, an-
thropometric and blood derived data, and can reliably ex-
clude advanced fibrosis with a high negative predictive
value (NPV) [60]; nonetheless, this approach is not suffi-
ciently validated and not widely used and accepted. Serum
biomarkers produced during fibrogenesis were investigate
to predict the presence of fibrosis. Rosenberg et al. made
an algorithm combining age, hyaluronic acid, amino-
terminal pro-peptide of type III collagen and tissue inhibi-
tor of matrix metalloproteinase-1 with high sensitivity and
specificity [61]. Another field of interest has been the
measurement of adiponectin in NAFLD patients who have
markedly lower plasma concentrations of this adipokine
than control subjects. Furthermore, low adiponectin levels
are strongly associated with the severity of liver histology
including steatosis, necroinflammation and fibrosis [62].
Hepatic apoptosis is an essential feature of NASH, so hep-
atic biomarkers of apoptosis were also investigated.
Plasma levels of caspase-generated cytokeratin 18 (CK-
18), a protein involved in the apoptosis cascade, correlate
with the amount of hepatocyte apoptosis and independ-
ently predict the presence of NASH [63]. A study on
NAFLD patients without a diagnosis of MS showed that
the haemoglobin level was the only variable independently
associated with NASH and fibrosis (>2). In this study, a
cutoff of 147 g/L of haemoglobin was proposed as pre-
dictor of advanced fibrosis, claiming high sensitivity and
specificity. The main hypothesis was that because haemo-
globin concentrations increased similarly with the increase
of blood viscosity, determining an increased peripheral re-
sistance and reduced hepatic perfusion, this behaviour has
been suggested to accelerate fibrosis. Furthermore, in-
creased iron storage in the liver could damage it through
oxidative stress and lipid peroxidation [64]; also, this ap-
proach, which appears quite conjectural and unpractical,
is not widely accepted. The microbial community of the
intestine consists of more than 500 species and many of
them have not been identified so far. The intestinal micro-
flora has many important functions, in particular to main-
tain the microbial barrier against established as well as
potential pathogens, and furthermore, it influences the
motility and perfusion of the intestinal wall and stimulates
the intestinal immune system, reducing bacterial trans-
location and producing vitamins [65]. It has been reported
that both in animal and human studies, obese individuals
have an aberrant and peculiar intestinal microbiota com-
position, which appears to be linked to the obese state it-
self and yet susceptible to dietary modulation and can
impact on weight loss in humans [66]. NAFLD and NASH
have been associated with small intestinal bacterial over-
growth (SIBO) and increase intestinal permeability in pa-
tients who underwent intestinal bypass. In animal modelswith SIBO and confirmed NASH histology, the disease re-
verts after antibiotic therapy. Several bacterial bioproducts
may be potentially hepatotoxic; the most involved in the
pathogenesis of NAFLD is a lipopolysaccharide endotoxin,
an element of the cell wall of Gram-negative bacteria,
absorbed during lipid absorption. It can stimulate in-
flammatory pathway and promote IR, hepatic steatosis
and fibrosis [67]. Studies have confirmed that intestinal
permeability and SIBO are increased in NAFLD patients
and that these factors are associated with the severity of
hepatic steatosis [68]. In normal circumstances, only small
amounts of endotoxin will cross from the intestinal lumen
into the systemic circulation and the absorbed endotoxin
will rapidly be removed by monocytes, particularly Kupffer
cells that are residents in the liver. Patients with NAFLD
are characterized by a significant increase in circulating
levels of endotoxin. Although no significant difference
in endotoxin levels was observed between patients with
simple steatosis (NAFLD) and patients with NASH,
endotoxin levels may represent an important, even not
established, early marker of potential liver abnormality
[69]. A comprehensive analysis of plasma lipids and ei-
cosanoid metabolites, quantified by mass spectrometry,
in NAFLD patients showed significantly increased total
plasma monounsaturated fatty acids and the increased
ratio of monounsaturated fatty acids/unsaturated fatty
acid with variations in polyunsaturated fatty acids indicat-
ing that NAFLD is associated with de novo lipogenesis.
Furthermore, eicosanoids and products of oxidation of the
inflammatory arachidonic acid by lipoxygenase are par-
ticularly affected during progression to NAFLD and then
NASH [70]. In brief, there is not yet any single tool or al-
gorithm sufficiently and practically reliable to diagnose
and differentiate NAFLD from NASH, whose diagnosis
still relies on a combination of serum and imaging
features.
New perspectives
The concept of interactome can also mean indirect inter-
actions among genes, i.e. genetic interactions, environ-
ment and personal behaviour, and this is the frame of the
present review. This can include many aspects and ap-
proach, which were used and challenged also in NAFLD.
Metabonomics is the study of metabolism and metabolic
response to stimuli; it is usually achieved through the stat-
istical analysis of the spectra obtained by nuclear magnetic
resonance spectroscopy and mass spectrometry [71]. 1H
NMR spectroscopy is used for identification of structures
in biofluids (cell media, urine, plasma), intact biopsy speci-
mens and tissues. Metabolomic strategies have been used
to study the pathogenic mechanism of metabolic syn-
drome, NAFLD and NASH. Several metabolites derived
from human and gut microbial co-metabolism have
been associated with phenotypes of metabolic syndrome.
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metabotypes can be treated like any other phenotype in
a genetic analysis, which means that variations of each
metabotype arise from genetic and environmental fac-
tors. The gut microbiome has a strong effect on host
metabolic phenotypes, which are relayed by complex
signaling pathways that connect organs such as the
liver, brain and immune system [71]. Methylamines are
a class of metabolites produced by the intestinal micro-
biota and were identified as markers of NAFLD in mice.
Metabolic profiling technologies could be used in a
clinical setting for epidemiological studies, prognosis
assessment and population stratification [71]. Moreover,
micro-RNAs (miRNAs) are an emerging class of highly
stable, non-coding small RNAs that regulate gene expres-
sion at the post-transcriptional level. Deregulation of
miRNA expression may be a key pathogenic factor in
many liver diseases. Dumas et al. demonstrate a serum
miRNA panel with considerable clinical value for the diag-
nosis of NAFLD [72].
In Germany, a national flagship research programme
called Virtual Liver Network (VLN) focuses on produ-
cing a validated computer model of human liver physi-
ology in order to improve the understanding of the
dynamics and the complex functions and applying this
to support clinical practice. Given its role in drug metab-
olism, these models could be used in the future to ana-
lyse patient-derived data and optimize drug efficacy and
patient safety [73].
Other authors developed a mathematical model of the
hepatic lipid dynamics to simulate the fate of fatty acids
in hepatocytes. According to this model, steatosis devel-
opment is based on the processes of hepatocyte swelling
and impaired hepatic microcirculation with a fundamen-
tal role of oxygen availability for lipid oxidation [74]. All
these techniques need future validations to be used in
the daily clinical practice but represent new interesting
insights in the study of the liver.
Suggestions for improving diagnostic reliability
In the daily practice, we suggest to exert greater efforts
than we do currently to better understand the clinical
frame of any individual patient. Reliable information on
the quality of diet and lifestyle are mandatory for pre-
dicting and preventing this liver disease which is associ-
ated with unhealthy dietary habits and sedentary life
and, at last, obesity. This is the only sustainable way to
address a personalized approach to management, which
includes diagnostic tools and the necessary follow-up
and therapeutic strategies. The fourth P, “participatory”,
is the key of this comprehensive approach: if the phys-
ician and the patient rely excessively, or exclusively, on
laboratory information and on pharmacological agents,
the battle against NAFLD is already lost. Non-invasiveimaging modalities are still the best surrogate of liver bi-
opsy, which is not warranted, unless the need of investi-
gating a different condition, and particularly cancer, is
present. Since also the outcome of the current pharmaco-
logical approaches is substantially disappointing, persona-
lization of medicine by participation is not only the
therapeutic step, but, much more, the diagnostic stage,
which includes a proactive patient-doctor relationship,
with the old-fashioned components of history, physical
examination and collateral information acquisition.Prevention and treatment
Diet Like biomarkers, studied to diagnose NASH non-
invasively, current therapies are focused on the various
pathways thought central in the pathogenesis of this dis-
ease. Often, patients with NAFLD are obese or overweight
and insulin resistant with higher energy intake with re-
spect to individuals without hepatic steatosis [75]. In some
nutritional reports, it has been suggested that high-fat,
high-fat plus low-protein, high-carbohydrate and/or high-
cholesterol diets are the main causes of NAFLD. Although
many NAFLD patients show excess caloric intake, obesity
and/or IR, not all patients present these features. In a
nutritional analysis on Japanese population, non-obese
NAFLD patients had some features that differed from
those of obese patients [76]. The dietary levels of total
calories, fat and carbohydrate were significantly higher
in obese NAFLD patients with IR than those in non-
obese NAFLD patients and healthy volunteers. The
most interesting finding was that cholesterol intake was
markedly higher in non-obese NAFLD patients than in
obese NAFLD patients, although cholesterol intake in
obese patients was also significantly higher than that
in healthy volunteers. Moreover, serum cholesterol levels
may be normal in NAFLD patients because dietary
cholesterol is promptly taken up into the hepatocyte
cholesterol pool [76]. Fatty liver without obesity can, in-
deed, be established in animal models by feeding them
with a hypercholesterolemic diet containing normal cal-
orie level [77]. Another study showed that mice treated
with trans fats in a high-fat diet and high-fructose corn
syrup in water, associated to sedentary behaviour, devel-
oped a severe phenotype of fatty liver disease with
necroinflammatory changes and a profibrogenic re-
sponse at the molecular level in the setting of obesity,
hepatic IR, impaired insulin responsiveness and hyper-
insulinemia. The presence of trans fats promoted fat re-
tention in the liver and contributed substantially to
hepatocellular injury; moreover, fructose is commonly
found in soft drinks and other carbohydrate-sweetened
beverages, the favourite drink of Western diet [78].
Fructose was originally promoted as a beneficial dietary
component because it does not stimulate insulin secretion.
Figure 7 PUFAs molecular mechanism of action. ω-3 PUFAs
regulate gene transcription factors, i.e. peroxisome proliferator-
activated receptor alpha (PPARα), PPARγ and sterol regulatory
element-binding protein-1 (SREBP-1), having a beneficial impact on
most of the cardiometabolic risk factors (hypertension, hyperlipidemia,
endothelial dysfunction and atherosclerosis). Activation of PPARs
stimulates lipid oxidation, decreases the endogenous lipid production
and determines IR, besides a significant reduction of the expression of
pro-inflammatory molecules (TNF-α and IL-6) and of oxygen reactive
species, leading to amelioration of hepatic steatosis.
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central mechanisms of satiety, this property of fructose
may be undesirable [78]. Furthermore, the consumption
of sucrose-sweetened soft drinks with a daily intake of
1 L results in a higher relative amount of VAT and liver
fat accumulation than isocaloric semi-skimmed milk,
aspartame-sweetened beverages and water [79]. A study
comparing fructose-sweetened and glucose-sweetened
beverages revealed that mainly fructose-containing
drinks increase visceral adiposity and lipids in over-
weight subjects [80]. The same authors reported that
subjects with MS consuming fructose-sweetened bever-
ages exhibited the largest decreases of postprandial fat
oxidation rates and increases of carbohydrate oxidation
rates.
Moreover, resting energy expenditure is reduced
compared to baseline values in subjects consuming
fructose-sweetened beverages [81]. Treatment of all
metabolic-associated conditions is crucial in NAFLD
therapy. Lifestyle modifications are effective in redu-
cing intrahepatic triacylglycerol concentration and circu-
lating liver enzymes and improving measures of glucose
control and/or insulin sensitivity in patients with NAFLD.
A study demonstrated that changes in dietary fat content
can modify liver fat within 2 weeks. The diet did not
change body weight, FFA concentrations and visceral or
subcutaneous fat mass, but liver fat decreased during the
low-fat diet and increased during the high-fat diet. The
changes in liver fat were paralleled by changes in fasting
serum insulin concentrations [82].
The use of omega-3 polyunsaturated fatty acids (ω-3
PUFAs) has been described as a potential treatment of
NAFLD [83] (Figure 7). ω-9 oleic acid is the most preva-
lent monounsaturated fatty acid (MUFA) in the diet, and
olive oil is one of its major sources (other sources are
nuts and avocado). Olive oil has traditionally been the
principal oil of the Mediterranean diet [84]. The benefi-
cial effect of MUFAs on the risk of cardiovascular dis-
ease and on lipid profile has been studied. Dietary oleic
acid decreased oxidized LDL, LDL cholesterol and TG
concentration without alterations in HDL levels. It has
been demonstrated that consumption of MUFAs de-
creases blood TGs by increasing fatty acid oxidation simi-
larly to PUFAs through activation of PPARα and PPARγ
and by reducing the activation of SREBP-1. This causes in-
hibition of lipogenesis, increase of lipid oxidation and de-
crease of IR, leading to a reduction in hepatic steatosis
[85]. MUFA diet prevents central body fat accumulation
and decreases postprandial adiponectin expression in-
duced by a carbohydrate-rich diet in insulin-resistant sub-
jects [86]. Additional effects of olive oil beyond its MUFA
composition relate to its polyphenols. Polyphenols present
in olive oil, such as oleuropein, hydroxytyrosol, tyrosol
and caffeic acid, have an important antioxidant and anti-inflammatory effect [85,87]. Among polyphenols, resvera-
trol, a component of several grape species, appears to be
particularly relevant in the context of liver disease. Resver-
atrol has anti-inflammatory effects inducing a decrease in
pro-inflammatory cytokines. Its administration reduces
portal pressure, hepatic stellate cell activation and liver fi-
brosis, and improves hepatic endothelial dysfunction in
cirrhotic rats [88]. In an interesting study, resveratrol re-
duced liver weight and TG content and does not modify
the activity of lipogenic enzymes but reduces non-
esterified fatty acids and alkaline phosphatase as well as
liver oxidative stress. This study demonstrates that resver-
atrol can protect the liver from NAFLD by reducing fatty
acid availability and oxidative stress [89]. Another study
reports that hepatic steatosis was significantly improved
and associated to a decreased TNF-α production in rats
treated with resveratrol. Authors think that the decreased
liver damage in a model of liver steatosis could be related
to its anti-TNF-α effect [90]. It may be a promising candi-
date treatment for NAFLD and NASH. Although alcohol
abuse is detrimental for liver, modest wine consumption is
associated with reduced prevalence of suspected NAFLD.
A recent study supports the safety of one glass of wine per
day for cardioprotection in patients at risk for both coron-
ary heart disease and NAFLD [91]. Another research
Table 2 Dietary supplements in NAFLD treatment
Dietary supplements Effects
PUFAs/MUFAs • Increase of fatty acid oxidation





• Antioxidant and anti-inflammatory effects
Soy proteins • Modulation of lipid and carbohydrate
metabolism
• Reduction of oxidative stress
Taurine • Increase of antioxidant defense
Coffee • Protection against fibrosis
• Anti-inflammatory effects
Choline • Influences liver function
Vitamin D • Suppression of fibroblast proliferation and
collagen production
• Effect on fat accumulation into the
hepatocytes
List of the dietary supplements, in which the effects were evaluated in the
treatment/therapy of non-alcoholic fatty liver disease.
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have a protection effect against IR in severely obese pa-
tients and it had no impact on the severity of activity and
stage of liver disease [92]. Studies have shown the role of
soy in the diet and its relation with NAFLD. Indeed, inter-
actions between soy protein, the isoflavonoid-enriched
fraction and amino acid pattern may reduce lipogenesis.
These soy components modulate lipid and carbohydrate
metabolism in the liver through the expression of related
transcription factors. One of the possible effects of soy is,
in fact, related to its ability to stimulate PPARα and inhibit
SREBP-1. Soy and its components might also increase per-
ipheral insulin sensitivity by reducing oxidative stress and
modulating pro-inflammatory cytokines [93]. In an animal
model, soy protein significantly lowered plasma choles-
terol concentrations and body fat accumulation; it de-
creased also the hepatic lipid depots of triacylglycerols
and cholesterol and the concentrations of lipid peroxide.
Furthermore, in an analysis of antioxidative status, rats fed
with a soy protein diet showed improved antioxidative po-
tential due to increases in superoxide dismutase and cata-
lase activities [94] confirming the protective role on liver
damage.
Another putatively promising substance is taurine,
naturally present in food, especially in seafood and
meat. Taurine reduced or prevented hepatic steatosis in
high-sucrose diet-fed rats. Although the mechanisms by
which taurine exerts its beneficial effects are unknown,
several possibilities were proposed. Substantial evidence
indicates that taurine protects a wide variety of cells
from oxidative damage by increasing antioxidant defense
systems, decreasing the formation of ROS and interfering
with ROS activity. Dietary supplementation with taurine
offers significant potential as a preventative treatment for
NAFLD [95]. Coffee is one of the most popular beverages
in the Western world. A recent study showed that con-
sumption of regular coffee was associated with a lower
level of fibrosis and was independently protective against
fibrosis in a cohort of severely obese patients undergoing
bariatric surgery. Moreover, total consumption of coffee in
different form, regular coffee and espresso, was not associ-
ated with NASH [96]. The methylxanthine caffeine, a
main component of coffee, may inhibit the synthesis of
connective tissue growth factor in liver parenchymal cells.
The gene expression in the liver and adipose tissues of
mice that were fed by a high-fat diet with added coffee
was investigated; in this model, a strong induction of anti-
inflammatory responses was found with lower levels of in-
flammatory cytokines (i.e. TNF-α, IL-6) resulting in an
improvement of fatty liver [97]. In human, coffee drinking
in patients with NAFLD is inversely associated with the
degree of bright liver appearance at US, with a trend op-
posite to overweightness. Authors hypothesized a possible
favourable and/or preventive role of coffee use in thenatural history of NAFLD [98]. Choline is a water-soluble
essential nutrient usually grouped within the B-complex
vitamins. It is found in meat, fish and egg but also in vege-
tables such as cauliflower. Choline influences liver func-
tion, and the dietary requirement for this nutrient varies
depending on an individual’s genotype and estrogen status.
It is unknown why some individuals develop NAFLD and
others do not and why some patients tolerate total paren-
teral nutrition and others develop liver dysfunction. Gut
microbiota may influence bioavailability of dietary choline
to the host and thereby contribute to the development of
NAFLD [99]. The role of vitamin D in the pathogenesis of
hepatic diseases is actually of great interest. In the liver,
vitamin D suppresses fibroblast proliferation and collagen
production. A strong independent association was found
between low 25 (OH) vitamin D levels and NAFLD; this
association is independent from diabetes, lipid profile al-
terations and IR. Besides, an inverse correlation between
serum 25 (OH) vitamin D levels and the degree of NAFLD
was observed, suggesting that vitamin D may exert a dose-
dependent effect on fat accumulation into the hepatocytes
[100]. In Table 2, we summarize several possible dietary
supplements, with their respective effects in NAFLD pa-
tients. Despite all these studies, and many others are avail-
able, the road of the search for the benefits, or the
disadvantage, of single nutrients, managed as they were
drugs, is substantially disappointing, and more realistic ap-
proaches address the assessment and the change of nutri-
tional profiles, whose healthy features are defined by
epidemiology and by some clinical and experimental evi-
dence [43].
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to improve health and quality of life by lifestyle changes
[101]. Lifestyle was originally introduced as a special de-
rivative of style in fashion and art. Nowadays, there is a
comprehensive frame of the factors interacting for main-
taining physical and mental health. These lifestyle factors
are deemed as crucial to an individual’s longevity and to
prevent disease, such as obesity and NAFLD. Few as-
pects of lifestyle are voluntary, and fashion and market-
ing are significant factors. Many fashion models may
have dual effects on health. The trend of ultra-slim
models has been limited from the runways for a while,
but now they are on the stage; these are effective and
beneficial icons of the fight against obesity throughout
the world. There is a relevant social “side effect” on
mental anorexia occurrence, which is quite questionable
and, probably, very limited. Also, unfavorable effects of
the opposite model can be detected. The universal avail-
ability of comfortable and wide clothing is contributing
to the enhancement of obesity. Fashion and health are
symbiotic. Fashion can make us stand straighter and
help prevent spine pain and osteoporosis. Fashion can
damage our feet and our balance through the choice of
shoes or it can exercise our leg muscles and improve
our gait. Fashion can protect us from the harsh rays of
the sun. Now, fashion aims even to monitor our health
through textile embedded electronic sensors. High heels
can cause poor posture, put pressure on joints and lead
to arthritis, hammer toes, back pain and tendon injuries.
Low-rise pants, “low-cut jeans”, “hipster jeans” and “low-
riders” intended to sit low on or below the hips may put
pressure on sensory lateral cutaneous nerve of the thigh,
which can cause pain and paresthesia in the nerve’s area
of distribution; also, effects on digestion, i.e. esophageal
reflux, constipation and others, are frequently observed.
Mostly breathable materials like cotton or linen reduce
yeast and fungal infections, and for men, wearing tight
trousers can cause overheating of the testes, lowering
sperm count and causing fertility problems. As re-
searchers attempt to conceptualize relationship among
different events, similarly, fashion designers attempt to
design clothes which are functional as well as aesthetic-
ally pleasing. The concept of functional, however, is not
yet comprehensive of healthy. There are still limited or
absent researches for a realistic paradigms of healthy
clothing, which currently means comfortable according
to weather, age and activity. Full interactive and compre-
hensive analysis of relationship of fashion, lifestyle, nu-
trition, physical exercise, health and disease is in
progress through the clinical investigation of a group of
youngsters within 14–35 years. By this approach, we
should achieve some information also regarding the rela-
tionship between sedentary life, also related to not ap-
propriately suited clothing, obesity and malnutrition,which not necessarily means underweight and other as-
pects which are strongly related to fashion models and
to media.
Despite that this is the actual scenario of lifestyle and
its implications cannot be oversimplified without losing
meaning and translational prospects, several investiga-
tions, also in humans, tried to simulate in experimental
subset lifestyle and its changes.
In a very significant study, healthy volunteers ate at least
two fast food-based meals a day, led a sedentary lifestyle
for 4 weeks, increasing in body weight of 5%–15%, and
underwent proton magnetic resonance spectroscopy (1H-
MRS) to evaluate hepatic triglyceride content (HTGC).
This change in lifestyle induced an alteration in ALT levels
and a visceral accumulation of adipose tissue as shown by
the significant rise of WC; a consistent increase of HTGC
also occurred, indicating a net retention of lipids within
hepatocytes [102]. Energy restriction, with and without in-
creased physical activity, and weight reduction were the
most frequently employed methods to reduce liver fatty
infiltration. Weight reductions of 4%–14% resulted in sta-
tistically significant relative reductions in reducing intra-
hepatic triacylglycerol concentration of 35%–81%. Low
(800–1,800 kcal/day) and very low-calorie diets (<800
kcal/day) and/or carbohydrate restriction (20–50 g/day)
resulted in the most rapid reductions in body weight and
NAFLD [103]. Another study showed a significant decline
in the aminotransferase levels in patients with NASH who
adhered to the aerobic exercise program regardless of
their weight loss. All these patients had a persistent eleva-
tion of serum aminotransferases prior to commencing ex-
ercise, and the fall in elevated liver enzymes was noticed
within 3 months of joining the program. Aerobic exercise
of sufficient intensity and duration has beneficial effects
on insulin sensitivity and alters substrate use in skeletal
muscle. Furthermore, the decrease in WC is likely to be
due to a decrease in abdominal fat stores. Exercise seems
to redistribute the fat stores in the body, which ultimately
leads to a decrease in visceral obesity and heightens the
insulin responsiveness in adipose tissue [104]. Moreover,
IR, WC, BMI and ALT levels correlate with histological
improvement of NAFLD [105]. Another study showed an
inverse relationship between vigorous-intensity physical
activity and NAFLD severity. Moderate-intensity physical
activity and total volume of physical activity were not re-
lated to outcomes. Thus, intensity may be an important
dimension of physical activity to consider when counsel-
ing patients and planning interventions [106]. Emerging
evidence suggests that obstructive sleep apnea (OSA), the
recurrent obstruction of the upper airway during sleep,
may play a role in the progression of hepatic steatosis and
the development of NASH. OSA results in fragmentation
of sleep and in recurrent oxyhaemoglobin desaturations
leading to intermittent hypoxia (IH). Recent studies
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predicted the severity of NAFLD on liver biopsy. Mouse
model showed that IH causes TG accumulation in the
liver and liver injury and hepatic inflammation. Several
causes are hypothesized: IH may worsen hepatic steato-
sis by inducing adipose tissue lipolysis, also through the
sympathetic nervous system, and increasing lipid bio-
synthetic pathways. IH up-regulates hypoxia-inducible
factor 1 alpha (HIF-1α) and possibly HIF-2α, which may
increase hepatic steatosis and induce liver inflammation
and fibrosis. IH may also up-regulate ROS generation via
NADPH oxidase system stimulating hepatic stellate lead-
ing to liver fibrosis [107]. Although OSA is associated with
manifestations of the metabolic syndrome, recent studies
in healthy human volunteers revealed that increasing HI is
associated with worsening insulin IR independent of obes-
ity [108]. Furthermore, IR and dyslipidemia induced by
OSA can be reversed by continuous positive airway pres-
sure. Patients may benefit from identification and treat-
ment for OSA because it may improve liver steatosis
[109]. Bariatric surgery is a specific treatment considered
in patients who have a BMI greater than 40 kg/m2 or with
a BMI of 35 kg/m2 who have obesity-related comorbidi-
ties. It induces weight loss by reducing the size of a pa-
tient’s stomach by either removing a portion of the
stomach, using a gastric band, or by gastric bypass. Several
studies have found that bariatric surgery has also effects
on insulin resistance, steatosis and liver inflammation.
The role and the validation of this treatment for NAFLD
is not clear, and future well-designed studies need to be
conducted [110]. Detrimental effects of marketing food in-
formation through misleading or actually fake message
must be understood, detected and counteracted: in this
sense, the active and informed participation of the patient
is the key and the premise for the further workup ad-
dressed to personalized therapy.
Drugs Use and effectiveness of drugs is very far from be-
ing demonstrated by the published studies challenging
benefits, if any, of the currently available drugs. Given that
IR plays a key role in the pathogenesis of NAFLD, many
studies have evaluated the use of insulin sensitizers for the
improvement of peripheral insulin sensitivity as a possible
treatment for this disease. Glitazones (TZDs) are agonists
of PPARγ nuclear receptors, superfamily which regulates
the transcription of genes involved in lipid metabolism
and plays a role in increasing insulin sensitivity as well as
in promoting fatty acid uptake into adipocytes. This class
of drugs also promote the differentiation of large, insulin-
resistant adipocytes into small, metabolically active,
insulin-sensitive adipocytes. TZDs decrease, then FFA in-
flux to the liver, decrease TNFα and increase adiponectin
production. One of the most reproducible effects of TZDs
is a reduction of aminotransferase levels by 30%–58%.This occurs early on with therapy. This effect is short after
drug discontinuation; a return to baseline levels usually
occurs within 3 months. Longer treatment (>1 year) does
not seem to have additional beneficial effects [111,112].
An intriguing trial compared the use of pioglitazone and
vitamin E for the treatment of non-alcoholic steatohepati-
tis in adults without diabetes. It showed that vitamin E
was superior to placebo and suggested that pioglitazone
may also have efficacy with highly significant reductions in
steatosis, inflammation and hepatocellular ballooning, as
well as with improvements in IR and liver-enzyme levels.
Neither agent was associated with a significant improve-
ment in the mean fibrosis score after 96 weeks of treat-
ment. The weight gain among the subjects receiving
pioglitazone with an increase of peripheral adipose tissue
and a concomitant decrease in VF content, which did not
resolve after discontinuation of the drug, also discourages
its long-term use [111,113].
Another insulin sensitizer is metformin. Its use as an
anti-diabetic drug is explained by its ability to lower
blood glucose by decreasing gluconeogenesis in the liver,
stimulating glucose uptake in the muscle and increasing
fatty acid oxidation in adipose tissue. Furthermore, it
helps reduce body weight in obese patients with and
without diabetes and induces a significant reduction in
total body fat and VF. Weight loss during metformin
treatment has been attributed to decreased net caloric
intake, probably through appetite suppression. Several
trials have evaluated the liver histology modification to-
gether with serum aminotransferase levels and IR show-
ing a marked amelioration in NAFLD patients treated
with metformin. In terms of histological improvement,
some trials showed significant differences in inflamma-
tion, steatosis and fibrosis after treatment with metfor-
min [113,114]. In contrast to these promising results,
some recent open-label studies have found no benefit of
metformin treatment in liver steatosis, aminotransferase
levels and IR markers compared to lifestyle changes or
control untreated group [115]. Ezetimibe, a blood
cholesterol-lowering agent, is a NPC1L1-specific inhibi-
tor and selectively blocks 54% of cholesterol absorption
from the intestine, but does not inhibit the absorption
of fat-soluble vitamins. In a recent study on non-obese
NAFLD patients showing excess intake of dietary chol-
esterol, ezetimibe therapy decreased serum ALT levels
and improved steatotic findings on ultrasonography in
some patients [116]. Statins (3-hydroxy-3-methylglutaryl-
coenzyme A reductase inhibitors) are used worldwide
to treat lipid disorders, particularly elevated low-density
lipoprotein-cholesterol and substantially reduce cardio-
vascular events and mortality. Although statins are pu-
tatively associated with some adverse events, including
elevated hepatic enzymes and liver dysfunction, an ele-
vated serum ALT level at baseline attributable to NAFLD
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vations in ALT. In clinical studies, simvastatin and ator-
vastatin were associated with a reduction in hepatic
steatosis and may inhibit the progression to NASH.
Four years of treatment with atorvastatin combined
with vitamins C and E reduced hepatic steatosis by 71%
in people with NAFLD at baseline. Taken together with
a previous report showing that excess cholesterol con-
sumption may accelerate NAFLD, statins may be prom-
ising candidates for the treatment of NAFLD [117,118].
Since PPARα is highly expressed in the liver and is in-
volved in fatty acid oxidation, fibrates and PPARα agonists
increase FFA oxidation in the liver, alter TG synthesis and
reduce hepatic synthesis of VLDL. A placebo-controlled
trial was performed to evaluate the effect of two classes of
pharmacological agents used to treat hypertriglyceridemia:
fenofibrate and nicotinic acid. Although intrahepatic TG
content was not affected by either treatment, both fenofi-
brate and niacin reduced plasma TG concentrations by al-
tering VLDL-TG metabolism. However, the mechanism
responsible for the change in VLDL-TG concentration is
different for each drug; fenofibrate increases plasma
VLDL-TG clearance, whereas nicotinic acid decreases
VLDL-TG secretion [119]. These findings are strength-
ened by another study on patients with non-alcoholic
fatty liver disease treated with fenofibrate that im-
proved metabolic syndrome and glucose and liver tests.
However, its effects on liver histology were minimal. Bi-
opsy after treatment, indeed, revealed a decrease in the
grade of hepatocellular ballooning degeneration, but
the grade of steatosis, lobular inflammation, fibrosis or
non-alcoholic fatty liver disease activity score did not
change significantly [120]. The renin-angiotensin sys-
tem (RAS) plays key roles in the regulation of blood
pressure and fluid balance, as well as in the pathogen-
esis of IR and NAFLD. In addition, inhibition of the
RAS may improve the intracellular insulin signaling
pathway, offering better control of adipose tissue prolifera-
tion and adipokine production. The two main classes of
RAS blockers are angiotensin II receptor blockers (ARBs)
and angiotensin-converting enzyme inhibitors (ACEIs).
ARBs have PPARγ-activating properties at low (telmisar-
tan), medium (irbesartan) and very high concentrations
(losartan) [121]. Valsartan prevented the pathological pro-
gression of hepatic fibrosis in type 2 diabetic rats, which
correlated with reducing TGF-β1 and TNF-α expression
and has also anti-apoptosis and mitochondria-protective
potential [122]. Losartan significantly decreased the stea-
tosis degree and the SAT and VAT diameters compared
with amlodipine therapy. The addition of simvastatin to
losartan therapy further decreased the steatosis degree
and the SAT and VAT diameters. Losartan and simvastatin
combination significantly improved the hepatic steatosis
indices compared with amlodipine and simvastatincombination [123]. Glucagon-like peptide-1 (GLP-1) is an
incretin secreted by L cells in the small intestine in re-
sponse to food intake. The main roles of GLP-1 are stimu-
lation of glucose-dependent insulin secretion, inhibition of
postprandial glucagon release, delay of gastric emptying
and induction of pancreatic β-cell proliferation. Treatment
with incretin modulators, GLP-1 analogs and dipeptidyl
peptidase-4 inhibitors reduces weight gain, minimizes
hypoglycemia, decreases inflammation and is cardio-
protective. Several trials evaluating the effects of exena-
tide (GLP-1 analog) in patients with diabetes revealed
that treatment lead to significant improvements of hep-
atic steatosis and hepatic markers, such as elevated liver
enzymes, and other cardiovascular risk factors [124-126].
The addition of pioglitazone to exenatide therapy was as-
sociated with a significantly greater reduction in hepatic
fat, a greater increase in circulating adiponectin in patients
with T2DM as compared to the therapy with pioglitazone
alone; moreover, the association therapy patients showed
lack of a significant alteration in body weight as compared
to the weight gain associated with pioglitazone therapy.
The ability of exenatide to reduce appetite and ameliorate
thiazolidinedione-induced weight gain may explain the
greater reduction in hepatic fat content observed with
combined exenatide and pioglitazone therapy [127]. Urso-
deoxycholic acid (UDCA) has hepatoprotective and anti-
apoptotic effects which could be beneficial in patients with
NASH. After ingestion, UDCA becomes the principal bile
acid in the liver, replacing more toxic hydrophobic bile
acids and stimulating secretion of bile acids. Since steato-
tic hepatocytes are more susceptible to necrosis and gen-
erate increased quantities of hydroperoxides resulting in
increased oxidative stress when exposed to hydrophobic
bile acids, UDCA may potentially ameliorate this type of
liver injury [128]. In addition to these effects, UDCA sta-
bilizes mitochondrial membranes and inhibits caspase ac-
tivation, having the net effect of inhibiting apoptosis,
which has been noted to be increased in patients with
NASH. Despite preliminary evidence suggesting a pos-
sible favourable effect of UDCA on liver injury in pa-
tients with NASH, a large randomized controlled trial
found no difference in biochemistry or liver histology
with UDCA or placebo after 2 years of treatment [128].
Although high-dose UDCA has anti-apoptotic and anti-
oxidative properties, it does not appear to normalize
aminotransaminase levels in patients with NASH [129].
In contrast, another trial showed that treatment with
high-dose UDCA was safe and improved aminotrans-
ferase levels, serum fibrosis non-invasive markers
(FibroTest) and metabolic parameter [130]. New inter-
est is focused on the farnesoid X receptor (FXR), a
transcription factor that is fundamental for different
pathways regulating lipid metabolism in the liver. FXR
is activated by physiologic concentrations of biliary
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therapeutic tools against NAFLD, insulin resistance and
liver fibrosis. Obeticholic acid (OCA, 6α-ethyl-
chenodeoxycholic acid) is a semi-synthetic derivative of
the primary human bile acid chenodeoxycholic acid,
the natural agonist of the farnesoid X receptor that in a
6-week clinical trial was well tolerated, increased insu-
lin sensitivity and reduced markers of liver inflamma-
tion and fibrosis in patients with type 2 diabetes
mellitus and non-alcoholic fatty liver disease [131].
Orlistat (Xenical) is a natural lipase inhibitor, impedes
then dietary triglyceride hydrolysis in the gut and re-
duces the absorption of dietary fat by 30%, improving
IR and lipid profile. In the liver, the suggested role of
orlistat is in reducing fatty infiltration and improving
hepatic fibrosis, with significant improvement in serum
levels of ALT, AST and lipids [132]. But in another trial,
orlistat did not enhance weight loss, improve liver en-
zymes and IR, or histopathology when associated to a
1,400 kcal/day diet plus vitamin E [133]. Furthermore,
orlistat, alone or in combination with ezetimibe had
more favourable effect on LDL and additionally im-
proved BMI, transaminase levels and insulin resistance
[134]. Pentoxifylline (PTX) is a methylxanthine that in-
hibits a number of pro-inflammatory cytokines including
TNF alpha and may have potential hepatoprotective, anti-
fibrogenic effects. This was suggested by in vitro studies
on HSCs [135] and confirmed by a recent randomized
placebo controlled trial that showed improved histological
features of NASH, and liver fibrosis, in patients treated
with PTX [136]. Since the known role of gut microbiota
in the pathogenesis of NAFLD, many study focused their
attention on the research of new therapies with probiotics.
In animal model, a multistrain preparation composed of
Streptococcus thermophilus and several species of Lactoba-
cillus and Bifidobacteria significantly reduced serum and
liver triglyceride concentrations. which is associated
with a reduction of fat mass. This supports the anti-
inflammatory and antioxidative activity of VSL#3 on liver,
which is responsible in the preventative effect of the early
onset of NASH [137]. Furthermore, in a clinical trial, a
tablet of 500 million Lactobacillus bulgaricus and Strepto-
coccus thermophilus improved liver aminotransferase
levels in patients with NAFLD [138]. More studies are
needed, but this is a new and fascinating approach to liver
disease.
Despite the appropriateness of these clinical researches
and trials, also challenging the possible favourable collat-
eral effects of drugs used for other diseases, such as ar-
terial hypertension and diabetes, results are still null or
disappointing.
The cornerstone of any approach is still based on
healthy nutrition and lifestyle enhancement, also by the
promotion of healthy diet paradigms [101,139-143].Relationship with adipogenic adenovirus infections [144],
other organ disease [145-149] and environment [150,151]
is equally important also for research and exploitation of
societal intervention [152,153] and represents a field of
applicative research behind the boundaries of nutrients,
nutritional profile and lifestyles, trying to involve wider
environmental and multi-organ approaches. Overall, the
pathways of the “magic bullets” for managing liver disease
and, particularly, NAFLD are not so straightforward. Spe-
cific food or beverage and their content nutrients could
have an effect on or modify the occurrence and course of
liver diseases, acute or chronic, and modulate or counter-
act the effects of natural or synthetic toxic substances.
Preliminary evidence supports the use of several nutra-
ceutical agents in the treatment of liver diseases for which
conventional therapies are limited. It is known that in
chronic liver disease, as in other conditions, malnutrition
occurs due often also to inappropriate nutritional behav-
iour, bias and counseling, and it is correlated with poorer
quality of life and greater mortality outcome. Anorexia,
nausea and constipation that frequently accompany liver
disease and reduce dietary intake can be present without
frank or severe liver disease but exerting unfavourable ef-
fects on liver by malabsorption and, as written above,
microbiome alterations. There is the evidence that some
dietary substances, such as silymarin, a flavonoid derived
from the seeds of Silybum marianum (milk thistle), are
useful in liver disease, probably by preventing lipid per-
oxidation. Its more active derivative drug, silybin, was
associated with improvement in liver enzymes, insulin
resistance and liver histology without increases in body
weight in NAFLD patients [154], but also this pharma-
cological approach is still a niche application, which,
even anecdotally, is of benefit, in our experience, for
several patients.
Suboptimal health Despite it is true that “experience
without theory is blind, but theory without experience is
mere intellectual play” (Immanuel Kant), translational
medicine, from models to practice, needs convincing evi-
dence and is confirmed by practitioners’ verification.
The current dissemination of lifestyle and nutritional
intervention is more market- than evidence-based, and
the use of non-conventional approaches requires a great
level of attention and care to their scientific proofs, if any
[155]: “a lie gets halfway around the world before the truth
has a chance to get its pants on” (Winston Churchill).
Everybody understands the reasons of research. Also in
medicine, research is a risky process: in these subsets,
“chance is always powerful and it is necessary that the
hook always be cast; in the pool where you least expect it,
there will be fish” (Ovid). Nonetheless, “chance favors the
prepared mind” (Louis Pasteur), and by this, innovation
and discoveries ensue. So many facts are known about
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welcome. But current facts, which address professional be-
haviours, are more driven by epidemiology than by mo-
lecular biology knowledge.
A great level of attention should be present in the as-
sessment of established or new knowledge: the drift
caused by inconsistent articles and reports, and scarcely
supported conclusions, prevents the dissemination of
more robust studies and valid approaches. It is not true
that the choices in the management of NAFLD areFigure 8 Is the clinic of NAFLD a hazard? It is not true that the
choices in the management of NAFLD are scarcely relevant, so that
can be taken by chance addressing more to one aspect or the other. A
great level of attention should be present in the assessment of
established or new knowledge: the drift caused by inconsistent
articles and reports, and scarcely supported conclusions, prevents
the dissemination of more robust studies and valid approaches. A
lie gets halfway around the world before the truth has a chance to
get its pants on. The clinic of liver disease is a comprehensive approach,
and the concept that one special issue can be the definite answer for
diagnosis or therapy is not achieved. “Luck is not chance, it’s toil;
fortune’s expensive smile is earned”.scarcely relevant, so that can be taken by chance ad-
dressing more to one aspect or the other (Figure 8).
The clinic of liver disease is a comprehensive approach,
and the concept that one special issue can be the defin-
ite answer for diagnosis or therapy is not achieved.
“Luck is not chance, it’s toil; fortune’s expensive smile
is earned” (Emily Dickinson). There is the need of a
wider awareness of ethics in medical research. It is not
only a matter of science integrity and research miscon-
duct, both problems with obvious costs which are diffi-
cult to measure [156]; it is also a more general matter
of national European research guidelines which are so
hard to find, that it is not likely can they then serve as
a framework for researchers. Moreover, how can re-
searchers cooperate in international research projects
with such diversity in guidelines? European countries
are not yet united when it comes to guiding scientific
integrity [157], and European rules of funding are provid-
ing a great help toward a greater rationalization of this
context. The task of assessing futility and—differently—
quality and innovation of ideas and approaches is still and
even more than previously in the minds of expert evalua-
tors, who are in the most appropriate position to inde-
pendently evaluate independent research. The visibility
of this independence can be provided by several behav-
iours, including also active interventions against publi-
cations questionable for methodology and unsupported
conclusion. In this sense, the work in the field of 4Ps
and NAFLD is a model of the articulation of basic
translational research and evidence-based clinical ap-
proaches and outcomes.
There is also the need of a deeper awareness of ethics
of competences in health professionals. The articulation
of knowledge, expertise and skills of medical doctors, di-
etitians, health psychologists and sport and physical ex-
ercise graduates is the necessary strategy for achieving
realistically beneficial lifestyle changes. These interven-
tions can be greatly personalized with specific procedure,
such as cardiorespiratory assessment tests, which are
currently used mostly in cardiac and respiratory rehabili-
tation for addressing the work of physiotherapists. An
appropriate intervention on NAFLD and obesity, such as
equally on hypertension, diabetes, depression and other
conditions for which the benefit of appropriate increase
of physical activity is recognized, includes the need of an
adequate involvement of certified health professionals.
Suboptimal health status (SHS) is considered to be an
intermediate status between disease and health, and is
characterized by a decline in vitality, in physiological
function and in the capacity for adaptation [158], and is
a more general condition which is well, comprehensively
and very diffusely identifiable in the perverse liaison of
obesity, fatty liver and unhealthy environment, social
conditioning and lifestyle [43,101,140-143,150,151]. It is
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multiple risk factors and low levels of awareness of their
suboptimal health status herald a looming epidemic of
life-threatening diseases [159]. Lifestyle is one of the
most important factors affecting health status and its
perception, particularly in youngsters, and relationship
of body size, shape and appearance perception with ac-
tual body measurements, such as weight, is strongly
influenced by media and, namely, by fashion’s trends, in
youngsters [160,161] and in workers [162]. For these
reasons, multidimensional assessment and intervention
aimed to favorable modifications of lifestyles including
food quality [163], sedentary life [164] and healthy sleep
[165], gender issues and gender discrimination, alcohol,
illicit drugs, bullying and nightlife habits [166], are
likely to move suboptimal health toward better health
profiles.
The concept of 4Ps in NAFLD is summarized by the
concise sentence of Albert Einstein: “The devil has put a
penalty on all things we enjoy in life. Either we suffer in
health or we suffer in soul or we get fat”. This is quite
hyperbolic, of course, but something is true: the task of
medical research and intervention is to make possible to
enjoy life also without things that make sufferance in
health and souls and which increase body fat. This
model is suitable for addressing prevention and useful
for monitoring improvement, worsening and adherence
with non-invasive imaging tools which allow targeted
approaches.Conclusions
The road for addressing straight-to-the-point predictive,
preventive and personalized medicine in obesity, fatty liver
and fibrosis epidemics must take into account the multi-
factorial pathogenesis of NAFLD. Diagnosis is confirma-
tory by imaging (ultrasound) and of exclusion again by
imaging and the absence of relevant signs of inflammation
attributable to liver disease. Numerous treatments for
various contributory risk factors have been proposed, but
there is no single validated therapy or association recom-
mended for all cases irrespective of the primary NAFLD
risk factors. A predictive, preventive, personalized and par-
ticipatory medicine approach must take into account sev-
eral perspectives related to this subject; a greater focus to
best evidences and established practice is suggested to get
sustainable and cost-benefit valuable outcomes by partici-
patory interventions (see list below). The strategic compo-
nents can be enhanced within comprehensive research
projects focused to societal issues and innovation, market
appeal and industry development, cultural acceptance and
sustainability.
Below are expert recommendations for the manage-
ment of obesity and fatty liver: wider use of expertise in morphologic non-invasive
tools and mainly ultrasound for liver and fat cell
mass and also with early undergraduate and
postgraduate teaching and training;
 use of knowledge and skills, with availability of
suitable software, in nutritional and physical activity
assessment and prescription according to validated
guidelines on lifestyles and also with early
undergraduate and postgraduate teaching and
training;
 articulated professional staff, patient-friendly,
with pro-active frames using health psychology
empowerment, adherence and self-efficacy
enhancement;
 research development strategies, warranting
evidence-based application and reappraisal of the
current practice and knowledge;
 collaboration with non-profit patient’s associations,
media, various institutions (schools, cities, trade and
work organization) with the aim of better managing
societal issues and enhancing participatory medicine.
The basis of participatory medicine is a greater wide-
spread awareness of a condition which is both a disease
and an easy documented and inclusive clue for associ-
ated diseases and unhealthy lifestyle. NAFLD, like it is,
is a suitable target for addressing prevention and is useful
for monitoring improvement, worsening and adherence
by non-invasive imaging tools which allow targeted
approaches.
The road to increasing knowledge of epidemiology,
mechanisms and biological signatures implies a coherent,
articulated and widespread increase of medical skills in
non-invasive diagnostic tools, particularly clinical ultra-
sound, and in intervention strategies effective on lifestyle
change. The latter include health psychology and nutritional
and physical exercise prescription expertise disseminated by
continuous medical education but, more important, by con-
crete curricula for training undergraduate students. It is
possible and recommended to do it by formal teaching of
ultrasound imaging procedures and of practical lifestyle
intervention strategies. Guidelines and requirements of re-
search project funding calls should be addressed also to
NAFLD and allied conditions and should encompass the
goal of training by research and the inclusion of participa-
tory medicine topics.
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